



1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.
INVENTION: : APOLIPOPROTEIN BIOPOLYMER MARKERS
PREDICTIVE OF TYPE II DIABETES
SERIAL NUMBER : 09/991,809
FILING DATE : November 23, 2001
EXAMINER: : (not assigned yet)
GROUP ART UNIT : 1632
ATTORNEY DOCKET NO. : 2132.111

RECEIVED
MAR 13 2003
TECH CENTER 1600/2900

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3-6-03

Susan Hess

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

- X Supplemental Information Disclosure Statement
- X Certification Pursuant to 37 C.F.R. §1.97(e)
- X Copy of International Search Report
- X PTO-1449
- X References

Respectfully Submitted,

Date: 3/5/03

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#10
JPP

INVENTOR/APPLICANT

: Jackowski et al.

INVENTION:

: APOLIPOPROTEIN BIOPOLYMER MARKERS
PREDICTIVE OF TYPE II DIABETES

SERIAL NUMBER

: 09/991,809

FILING DATE

: November 23, 2001

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1632

ATTORNEY DOCKET NO.

: 2132.111

RECEIVED
MAR 13 2003
TECH CENTER 1600/2900

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3-6-03

Commissioner for Patents
Washington, D.C. 20231

Susan Hess

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date:

3/5/03

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: Jackowski et al.

INVENTION:

: APOLIPOPROTEIN BIOPOLYMER MARKERS
PREDICTIVE OF TYPE II DIABETES

SERIAL NUMBER

: 09/991,809

FILING DATE

: November 23, 2001

EXAMINER:

: (not assigned yet)

GROUP ART UNIT

: 1632

ATTORNEY DOCKET NO.

: 2132.111

RECEIVED
MAR 13 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for
Patents, Washington, D.C. 20231 on 3/5/03
Susan Tress

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date: 3/5/03

Respectfully Submitted,

Ferris H. Lander

Ferris H. Lander
Reg. No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 402
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575